Diasorin Logo

Diasorin

Develops immunodiagnostic and molecular diagnostic kits and systems for healthcare and research.

DIA | XMIL

Overview

Corporate Details

ISIN(s):
IT0003492391 (+2 more)
LEI:
8156002878BDF0EE4348
Country:
Italy
Address:
VIA CRESCENTINO, SNC, 13040 SALUGGIA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Diasorin is a global leader in the in vitro diagnostics (IVD) market, specializing in the development, manufacturing, and commercialization of reagent kits and automated systems. The company's core focus is on two primary segments: immunodiagnostics and molecular diagnostics. In immunodiagnostics, Diasorin provides advanced solutions, including its LIAISON® family of analyzers, which detect antibodies and antigens to aid in the diagnosis of diseases. Its molecular diagnostics division offers flexible tools that use targeted and multiplex technologies to identify pathogens in biological specimens, providing healthcare providers with critical, actionable information. The company also operates in the Licensed Technology sector, offering platforms for biomedical research, clinical diagnostics, and drug discovery to help scientists find rapid and reliable answers to complex biological questions.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-10 10:42
Director's Dealing
Comunicato Internal Dealing
Italian 94.9 KB
2025-11-05 17:44
Regulatory News Service
Diasorin 9M 2025 Results Presentation
Italian 2.2 MB
2025-11-05 17:43
Earnings Release
Diasorin’s Board of Directors approves results for the first 9 months of 2025. …
English 362.4 KB
2025-11-05 17:42
Earnings Release
Il Consiglio di Amministrazione di Diasorin approva i risultati dei primi 9 mes…
Italian 478.5 KB
2025-10-07 10:03
Declaration of Voting Results & Voting Rights Announcements
Communication on total amount of voting rights
English 229.7 KB
2025-10-07 10:01
Declaration of Voting Results & Voting Rights Announcements
Comunicazione dell'ammontare complessivo dei diritti di voto
Italian 210.3 KB
2025-09-05 10:34
Declaration of Voting Results & Voting Rights Announcements
Communication on total amount of voting rights
English 206.3 KB
2025-09-05 10:32
Declaration of Voting Results & Voting Rights Announcements
Comunicazione dell'ammontare complessivo dei diritti di voto
Italian 209.6 KB
2025-08-07 11:29
Interim Report
Interim Financial Report as at June 30, 2025
English 3.0 MB
2025-08-04 16:51
Report Publication Announcement
Pubblicazione della Relazione finanziaria semestrale al 30 giugno 2025
Italian 184.4 KB
2025-08-04 15:32
Interim Report
Relazione Finanziaria Semestrale del Gruppo Diasorin al 30 giugno 2025
Italian 3.4 MB
2025-07-31 16:24
Investor Presentation
Diasorin H1 2025 Results Presentation
English 1.4 MB
2025-07-31 16:22
Earnings Release
Revenue Growth and Margin Expansion in H1 2025. FY 2025 Guidance Confirmed
English 342.3 KB
2025-07-31 16:21
Earnings Release
Ricavi in crescita ed incremento della marginalità nel 1° semestre 2025. Confer…
Italian 470.4 KB
2025-07-07 09:34
Declaration of Voting Results & Voting Rights Announcements
Communication on total amount of voting rights
English 210.5 KB

Automate Your Workflow. Get a real-time feed of all Diasorin filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Diasorin

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Diasorin via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden
2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
ABEONA THERAPEUTICS INC. Logo
Developing AAV-based cell and gene therapies for serious and rare diseases.
United States of America
ABEO
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden
ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom
ABDX

Talk to a Data Expert

Have a question? We'll get back to you promptly.